Nectar Lifesciences will sell its active pharmaceutical ingredients, formulation, and menthol business assets to Ceph Lifesciences for ₹1,290 crore. This strategic move involves a Business Transfer Agreement for the core API and formulation business at ₹1,270 crore and an Asset Purchase Agreement for the menthol business at ₹20 crore.